Switching virally suppressed HIV-1 infected elderly adults (age above 60 years) without prior confirmed virological failure from current anti-retroviral regimen to bictegravir, emtricitabine and tenofovir alafenamide – BFTAF Study

Principle Instigator
Dr. Loice Achieng